Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.

Marshall, Helen S; Vesikari, Timo; Richmond, Peter C; Wysocki, Jacek; Szenborn, Leszek; Beeslaar, Johannes; Maguire, Jason D; Balmer, Paul; O'Neill, Robert; Anderson, Annaliesa S; Prégaldien, Jean-Louis; Maansson, Roger; Jiang, Han-Qing; Perez, John L

Marshall, Helen S; Vesikari, Timo; Richmond, Peter C; Wysocki, Jacek; Szenborn, Leszek; Beeslaar, Johannes; Maguire, Jason D; Balmer, Paul; O'Neill, Robert; Anderson, Annaliesa S; Prégaldien, Jean-Louis; Maansson, Roger; Jiang, Han-Qing; Perez, John L.

Afiliação

Marshall HS; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, North Adelaide, SA, Australia; Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. Electronic address: helen.marshall@adelaide.edu.au.
Vesikari T; Nordic Research Network, Tampere, Finland.
Richmond PC; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, WA, Australia; Perth Children's Hospital, Nedlands, WA, Australia.
Wysocki J; Poznan University of Medical Sciences, Poznan, Poland.
Szenborn L; Clinical Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland.
Beeslaar J; Pfizer Vaccine Clinical Research and Development, Hurley, UK.
Maguire JD; Pfizer Vaccine Clinical Research and Development, Pearl River, NY, USA.
Balmer P; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA.
O'Neill R; Pfizer Vaccine Research and Development, Pearl River, NY, USA.
Anderson AS; Pfizer Vaccine Research and Development, Pearl River, NY, USA.
Prégaldien JL; Pfizer Vaccine Clinical Research and Development, Brussels, Belgium.
Maansson R; Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA.
Jiang HQ; Pfizer Vaccine Clinical Research and Development, Pearl River, NY, USA.
Perez JL; Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA.

Lancet Infect Dis ; 23(1): 103-116, 2023 01.

Article em En | MEDLINE | ID: mdl-36087588

Assuntos

Infecções Meningocócicas; Vacinas Meningocócicas; Neisseria meningitidis Sorogrupo B; Humanos; Criança; Adolescente; Pré-Escolar; Proteínas de Transporte; Sorogrupo; Austrália; Infecções Meningocócicas/prevenção & controle; Imunogenicidade da Vacina

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Meningocócicas / Neisseria meningitidis Sorogrupo B / Infecções Meningocócicas Tipo de estudo: Clinical_trials / Guideline Limite: Adolescent / Child / Child, preschool / Humans País/Região como assunto: Oceania Idioma: En Revista: Lancet Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google